Not known Facts About YX-2-107
The first conclude issue was the protection and tolerability of sifalimumab. Therapy-emergent adverse events (AEs) and major AEs (SAEs) as well as their severity, result, and any connection to the review medication have been recorded by the investigator all over the research. AEs have been considered more likely to be associated with study medicati